Stem cell therapy for Parkinson's disease

Dialogues in Clinical Neuroscience

Volumn 6, Issue 3, 2004, Pages 303-311

  Björklund, Lars M ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Differentiation; Dopamine; Embryonic stem cell; Neural progenitor; Neurogenesis; Ventral mesencephalon

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 4 AMINOBUTYRIC ACID; BRAIN DERIVED NEUROTROPHIC FACTOR; CYTOKINE; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 8; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; INTERLEUKIN 1; INTERLEUKIN 11; LEUKEMIA INHIBITORY FACTOR; LEVODOPA; RETINOIC ACID; SONIC HEDGEHOG PROTEIN; TRANSFORMING GROWTH FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CELL SURVIVAL; DOPAMINERGIC NERVE CELL; EMBRYO; ETHICS; GERM CELL; HUMAN; HUMAN CELL; MESENCEPHALON; MOUSE; NERVE CELL DIFFERENTIATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIMATE; STEM CELL; STEM CELL TRANSPLANTATION;

EID: 5444238034     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (113)

1. Madrazo I, Leon V, Torres C, et al. Transplantation of fetal substantia nigra and adrenal medulla to the caudate putamen in two patients with Parkinson's disease. N Engl J Med. 1988;318:51.
2. Backlund E, Granberg P, Hamberger B, et al. Transplantation of adrenal medullary tissue to striatum in parkinsonism. J Neurosurg. 1985;62:169-173.
3. Freed WJ, Molikisa JM, Spool E, et al. Transplanted adrenal chromaffin cells in rat brain reduce lesion-induced rotational behaviour. Nature. 1981;292:351-352.
4. Bjorklund A, Stenevi U. Reconstruction of the nigrostriatal dopamine pathway by intracerebral nigral transplants. Brain Res. 1979;177:555-560.
5. Perlow MJ, Freed WJ, Hoffer BJ, et al. Brain grafts reduce motor abnormalities produced by destruction of nigrostriatal dopamine system. Science. 1979;204:643-647.
6. Brundin P, Duan W, Sauer H. Functional effects of mesencephalic dopamine neurons and adrenal chromaffin cells grafted to the rodent striatum. In: Dunnett S, Bjorklund A, eds. Functional Neural Transplantation. Vol 2. New York, NY: Raven Press; 1994:9-46.
7. Annett LE, Martel FL, Rogers DC, et al. Behavioral assessment of the effects of embryonic nigral grafts in marmosets with unilateral 6-OHDA lesions of the nigrostriatal pathway. Exp Neurol. 1994;125:228-246.
8. Bjorklund A, Dunnett SB, Stenevi V, Lewis ME, Iversen SD. Reinnervation of the denervated striatum by substantia nigra transplants: functional consequences as revealed by pharmacological and sensorimotor testing. Brain Res. 1980;199:307-333.
9. Carder RK, Snyder-Keller AM, Lund RD. Behavioral and anatomical correlates of immunologically induced rejection of nigral xenografts. J Comp Neurol. 1988;277:391-402.
10. Dunnett SB, Hernandez TD, Summerfield A, Jones GH, Arbuthnott G. Graft-derived recovery from 6-OHDA lesions: specificity of ventral mesencephalic graft tissue. Exp Brain Res. 1988;71:411-424.
11. Brownell AL, Livni E, Galpern W, Isacson O. In vivo PET imaging in rat of dopamine terminals reveals functional neural transplants. Ann Neurol. 1998;43:387-390.
12. Freed CR, Breeze RE, Rosenberg NL, et al. Transplantation of human fetal dopamine cells for Parkinson's disease. Results at 1 year. Arch Neurol. 1990;47:505-512.
13. Lindvall O, Rehncrona S, Gustavii B, et al. Fetal dopamine-rich mesencephalic grafts in Parkinson's disease. Lancet. 1988;2:1483-1484.
14. Bjorklund A, Dunnett SB, Brundin P, et al. Neural transplantation for the treatment of Parkinson's disease. Lancet Neurol. 2003;2:437-445.
15. Hagell P, Piccini P, Bjorklund A, et al. Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci. 2002;5:627-628.
16. Piccini P, Lindvall O, Bjorklund A, et al. Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. Ann Neurol. 2000;48:689-695.
17. Brundin P, Pogarell O, Hagell P, et al. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. Brain. 2000;123(Pt 7):1380-1390.
18. Piccini P, Brooks DJ, Bjorklund A, et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat Neurosci. 1999;2:1137-1140.
19. Hagell P, Schrag A, Piccini P, et al. Sequential bilateral transplantation in Parkinson's disease: effects of the second graft. Brain. 1999;122(Pt 6):1121-1132.
20. Wenning GK, Odin P, Morrish P, et al. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Ann Neurol. 1997;42:95-107.
21. Widner H, Tertrud J, Rehncrona S, et al. Fifteen months' follow-up on bilateral embryonic mesencephalic grafts in two cases of severe MPTP-induced parkinsonism. Adv Neurol. 1993;60:729-733.
22. Widner H, Tertrud J, Rehncrona S, et al. Bilateral fetal mesencephalic grafting in two patients with severe parkinsonism induced by MPTP. N Engl J Med. 1992;327:1556-1563.
23. 18F]-6-L-fluorodopa studies in two patients with putamina implants. Ann Neurol. 1992;31:166-173.
24. Lindvall O, Widner H, Rehncrona S, et al. Transplantation of fetal dopamine neurons in Parkinson's disease: 1-year clinical and neurophysiological observations in two patients with putaminal implants. Ann Neurol. 1992;31:155-165.
25. Lindvall O, Brundin P, Widner H, et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science. 1990;247:574-577.
26. Lindvall O, Rehncrona S, Brundin P, et al. Neural transplantation in Parkinson's disease: the Swedish experience. Prog Brain Res. 1990;82:729-734.
27. Lindvall O, Brundin P, Rehncrona S, et al. Human fetal dopamine neurons grafted into the striatum in two patients with severe Parkinson's disease: a detailed account of methodology and a 6-month follow-up. Arch Neurol. 1989;46:615-631.
28. Breeze RE, Wells TH Jr, Freed CR. Implantation of fetal tissue for the management of Parkinson's disease: a technical note. Neurosurgery. 1995;36:1044-1047. Discussion. 1995;36:1047-1048.
29. Freed CR, Breeze RE, Rosenberg NL, et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. N Engl J Med. 1992;327:1549-1555.
30. Freed CR, Rosenberg NL, Schneck SA, Breeze RE. Improved drug responsiveness following fetal tissue implant for Parkinson's disease. Neurochem Int. 1992;20(suppl):321S-327S.
31. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med. 2001;344:710-719.
32. Olanow CW, Goetz CG, Koldower JH, et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol. 2003;54:403-414.
33. Freed CR. Will embryonic stem cells be a useful source of dopamine neurons for transplant into patients with Parkinson's disease? Proc Natl Acad Sci USA. 2002;99:1755-1757.
34. Arenas E. Stem cells in the treatment of Parkinson's disease. Brain Res Bull. 2002;57:795-808.
35. Isacson O. The production and use of cells as therapeutic agents in neurodegenerative diseases. Lancet Neurol. 2003;2:417-424.
36. Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. Nature. 1981;292:154-156.
37. Martin GR. Isolation of a pleuripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc Natl Acad Sci U S A. 1981;78:7634-7638.
38. Pederson RA. Embryonic stem cells for medicine. Sci Am. 1999;April:68-73.
39. Sherman MI, Miller RA, Richter CB. Histologic analyses of experimental tumors from mouse blastocyst-derived cell lines. J Natl Cancer Inst. 1977;58:993-1002.
40. Bain G, Kitchens D, Yao M, Huettner JE, Gottlieb DI. Embryonic stem cells express neuronal properties in vitro. Dev Biol. 1995;168:342-357.
41. Barberi T, Klivenyi P, Calingasan NY, et al. Neural subtype specification of fertilization and nuclear transfer embryonic stem cells and application in parkinsonian mice. Nat Biotechnol. 2003;21:1200-1207.
42. Tropepe V, Hitoshi S, Sirard C, et al. Direct neural fate specification from embryonic stem cells. A primitive mammalian neural stem cell stage acquired through a default mechanism. Neuron. 2001;30:65-78.
43. Munoz-Sanjuan I, Brivanlou AH. Neural induction, the default model and embryonic stem cells. Nat Rev Neurosci. 2002;3:271-280.
44. Deacon T, Dinsmou J, Costantini LC, Ratliff J, Isacson O. Blastula-derived stem cells can differentiate into dopaminergic and serotonergic neurons after transplantation. Exp Neurol. 1998;149:28-41.
45. Bjorklund LM, Sanchez-Pernaute R, Chung S, et al. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci U S A. 2002;99:2344-2349.
46. Lee SH, Lumelsky N, Studer L, Averback JM, McKay RD. Efficient generation of midbrain and hindbrain neurons from mouse embryonic stem cells. Nat Biotechnol. 2000;18:675-679.
47. Chung S, Sonntag KC, Andersson T, et al. Genetic engineering of mouse embryonic stem cells by Nurr1 enhances differentiation and maturation into dopaminergic neurons. Eur J Neurosci. 2002;16:1829-1838.
48. Kim JH, Averback JM, Rodriguez-Gomez JA, et al. Dopamine neurons derived from embryonic stem cells function in an animal model of Parkinson's disease. Nature. 2002;418:50-56.
49. Nishimura F, Yoshikawa M, Kanda S, et al. Potential use of embryonic stem cells for the treatment of mouse parkinsonian models: improved behavior by transplantation of in vitro differentiated dopaminergic neurons from embryonic stem cells. Stem Cells. 2003;21:171-180.
50. Kawasaki H, Mizuseki K, Nishikawa S, et al. Induction of midbrain dopaminergic neurons from ES cells by stromal cell-derived inducing activity. Neuron. 2000;28:31-40.
51. Wakayama T, Tabar V, Rodriguez I, et al. Differentiation of embryonic stem cell lines generated from adult somatic cells by nuclear transfer. Science. 2001;292:740-743.
52. Ying QL, Stavridis M, Griffiths D, Li M, Smith A. Conversion of embryonic stem cells into neuroectodermal precursors in adherent monoculture. Nat Biotechnol. 2003;21:183-186.
53. Thomson JA, Kalishman J, Golos TG, et al. Isolation of a primate embryonic stem cell line. Proc Natl Acad Sci U S A. 1995;92:7844-7848.
54. Thomson JA, Kalishman J, Golos TG, et al. Pluripotent cell lines derived from common marmoset (Callithrix jacchus) blastocysts. Biol Reprod. 1996;55:254-259.
55. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cells derived from human blastocysts. Science. 1998;282:1145-1147.
56. Kawasaki H, Suemori H, Mizuseki K, et al. Generation of dopaminergic neurons and pigmented epithelia from primate ES cells by stromal cell-derived inducing activity. Proc Natl Acad Sci U S A. 2002;99:1580-1585.
57. Vrana KE, Hipp JD, Goss AM, et al. Nonhuman primate parthenogenetic stem cells. Proc Natl Acad Sci USA. 2003;100(suppl 1):11911-11916.
58. Zhang SC, Wernig M, Duncan ID, Brustle O, Thomson JA. In vitro differentiation of transplantable neural precursors from human embryonic stem cells. Nat Biotechnol. 2001;19:1129-1133.
59. Carpenter MK, Inokuma MS, Denham J, et al. Enrichment of neurons and neural precursors from human embryonic stem cells. Exp Neurol. 2001;172:383-397.
60. Reubinoff BE, Itsykson P, Turetsky T, et al. Neural progenitors from human embryonic stem cells. Nat Biotechnol. 2001;19:1134-1140.
61. Matsui Y, Zsebo K, Hogan BL. Derivation of pluripotential embryonic stem cells from murine primordial germ cells in culture. Cell. 1992;70:841-847.
62. Shamblott MJ, Axelman J, Wang S, et al. Derivation of pluripotent stem cells from cultured human primordial germ cells. Proc Natl Acad Sci USA. 1998;95:13726-13731.
63. Kerr DA, Llado J, Shamblott MJ, et al. Human embryonic germ cell derivatives facilitate motor recovery of rats with diffuse motor neuron injury. J Neurosci. 2003;23:5131-5140.
64. Johe KK, Hazel TG, Muller T, Dugish-Diordjevic MM, McKay RD. Single factors direct the differentiation of stem cells from the fetal and adult central nervous system. Functions of basic fibroblast growth factor and neurotrophins in the differentiation of hippocampal neurons. Genes Dev. 1996;10:3129-3140.
65. Reynolds BA, Weiss S. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science. 1992;255:1707-1710.
66. Daadi MM, Weiss S. Generation of tyrosine hydroxylase-producing neurons from precursors of the embryonic and adult forebrain. J Neurosci. 1999;19:4484-4497.
67. Carpenter MK, Cui X, Hu ZY, et al. In vitro expansion of a multipotent population of human neural progenitor cells. Exp Neurol. 1999;158:265-278.
68. Svendsen CN, Caldwell MA, Shen J, et al. Long-term survival of human central nervous system progenitor cells transplanted into a rat model of Parkinson's disease. Exp Neurol. 1997;148:135-146.
69. Yang M, Stull ND, Berk MA, Snyder EY, Iacovitti L. Neural stem cells spontaneously express dopaminergic traits after transplantation into the intact or 6-hydroxydopamine-lesioned rat. Exp Neurol. 2002;177:50-60.
70. Ourednik J, Ourednik V, Lynch WP, Schachner M, Snyder EY. Neural stem cells display an inherent mechanism for rescuing dysfunctional neurons. Nat Biotechnol. 2002;20:1103-10.
71. Zetterstrom RH, Solomin L, Jansson L, et al. Dopamine neuron agenesis in Nurr1-deficient mice. Science. 1997;276:248-250.
72. Wagner J, Akerud P, Castro DS, et al. Induction of a midbrain dopaminergic phenotype in Nurr1-overexpressing neural stem cells by type 1 astrocytes. Nat Biotechnol. 1999;17:653-659.
73. Lee VMY, Andrews PW. Differentiation of NTERA-2 clonal human embryonal carcinoma cells into neurons involves the induction of all three neurofilament proteins. J Neurosci. 1986;6:514-521.
74. Iacovitti L, Stull ND. Expression of tyrosine hydroxylase in newly differentiated neurons from a human cell line (hNT). Neuroreport. 1997;8:1471-1474.
75. Zigova T, Barroso LF, Willing AE, et al. Dopaminergic phenotype of hNT cells in vitro. Brain Res Dev Brain Res. 2000;122:87-90.
76. Saporta S, Willing AE, Colina LO, et al. In vitro and in vivo characterization of hNT neuron neurotransmitter phenotypes. Brain Res Bull. 2000;53:263-268.
77. Baker KA, Hong M, Sadi D, Mendez I. Intrastriatal and intranigral grafting of hNT neurons in the 6-OHDA rat model of Parkinson's disease. Exp Neurol. 2000;162:350-360.
78. Meyer M, Johansen J, Gramsbergen JB, Johansen TE, Zimmer J. Improved survival of embryonic porcine dopaminergic neurons in coculture with a conditionally immortalized GDNF-producing hippocampal cell line. Exp Neurol. 2000;164:82-93.
79. Ostenfeld T, Tai YT, Martin P, et al. Neurospheres modified to produce glial cell line-derived neurotrophic factor increase the survival of transplanted dopamine neurons. J Neurosci Res. 2002;69:955-965.
80. Akerud P, CAnals JM, Snyder EY, Arenas E. Neuroprotection through delivery of glial cell line-derived neurotrophic factor by neural stem cells in a mouse model of Parkinson's disease. J Neurosci. 2001;21:8108-8118.
81. Akerud P, HOm PC, Castelo-Branco G, et al. Persephin-overexpressing neural stem cells regulate the function of nigral dopaminergic neurons and prevent their degeneration in a model of Parkinson's disease. Mol Cell Neurosci. 2002;21:205-222.
82. Gill SS, Patel NK, Hotton GR, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med. 2003;9:589-595.
83. Studer L, Tabar V, McKay RD. Transplantation of expanded mesencephalic precursors leads to recovery in parkinsonian rats. Nat Neurosci. 1998;1:290-295.
84. Studer L, Csete M, Lee SH, et al. Enhanced proliferation, survival, and dopaminergic differentiation of CNS precursors in lowered oxygen. J Neurosci. 2000;20:7377-7383.
85. Yan J, Studer L, McKay RD. Ascorbic acid increases the yield of dopaminergic neurons derived from basic fibroblast growth factor expanded mesencephalic precursors. J Neurochem. 2001;76:307-311.
86. Sanchez-Pernaute R, Studer L, Bankiewicz KS, Major EO, McKay RD. In vitro generation and transplantation of precursor-derived human dopamine neurons. J Neurosci Res. 2001;65:284-288.
87. Brundin P, Bjorklund A. Survival of expanded dopaminergic precursors is critical for clinical trials. Nat Neurosci. 1998;1:537.
88. Ling ZD, Potter ED, Lipton JW, Carvey PM. Differentiation of mesencephalic progenitor cells into dopaminergic neurons by cytokines. Exp Neurol. 1998;149:411-423.
89. Potter ED, Ling ZD, Carvey PM. Cytokine-induced conversion of mesencephalic-derived progenitor cells into dopamine neurons. Cell Tiss Res. 1999;296:235-246.
90. Carvey PM, Ling ZD, Sortwell CE, et al. A clonal line of mesencephalic progenitor cells converted to dopamine neurons by hematopoietic cytokines: a source of cells for transplantation in Parkinson's disease. Exp Neurol. 2001;171:98-108.
91. Storch A, Paul G, Csete M, et al. Long-term proliferation and dopaminergic differentiation of human mesencephalic neural precursor cells. Exp Neurol. 2001;170:317-325.
92. Riaz SS, Jauniaux E, Stern GM, Bradford HF. The controlled conversion of human neural progenitor cells derived from foetal ventral mesencephalon into dopaminergic neurons in vitro. Brain Res Dev Brain Res. 2002;136:27-34.
93. Altman J. Are new neurons formed in the brains of adult mammals? Science. 1962;135:1127-1128.
94. Richards LJ, Kilpatrick TJ, Battlett PF. De novo generation of neuronal cells from the adult mouse brain. Proc Natl Acad Sci U S A. 1992;89:8591-8595.
95. Gage FH, Coates PW, PAlmer TD. Survival and differentiation of adult neuronal progenitor cells transplanted to the adult brain Proc Natl Acad Sci USA. 1995;92:11679-11883.
96. Palmer TD, Takahashi J, Gage FH. The adult rat hippocampus contains primordial neural stem cells. Mol Cell Neurosci. 1997;8:389-404.
97. Kempermann G, Wiskott L, Gage FH. Functional significance of adult neurogenesis. Curr Opin Neurobiol. 2004;14:186-91.
98. Fallon J, reid S, Kinyamu R, et al. In vivo induction of massive proliferation, directed migration, and differentiation of neural cells in the adult mammalian brain. Proc Natl Acad Sci U S A. 2000;97:14686-14691.
99. Zhao M, Momma S, Delfani K, et al. Evidence for neurogenesis in the adult mammalian substantia nigra. Proc Natl Acad Sci U S A. 2003;100:7925-7930.
100. Lie DC, Dziewczapolski G, Willhoite AR, et al. The adult substantia nigra contains progenitor cells with neurogenic potential. J Neurosci. 2002;22:6639-6649.
101. Iacopino AM, Christakos S. Specific reduction of calcium-binding protein (28-kilodalton calbindin-D) gene expression in aging and neurodegenerative diseases. Proc Natl Acad Sci U S A. 1990;87:4078-4082.
102. Yamada T, McGeer PL, Baimbridge KG, McGeer EG. Relative sparing in Parkinson's disease of substantia nigra dopamine neurons containing calbindin-D28K. Brain Res. 1990;526:303-307.
103. Ito H, Goto S, Sakamoto S, Hirano A. Calbindin-D28k in the basal ganglia of patients with parkinsonism. Ann Neurol. 1992;32:543-550.
104. Gibb WR. Melanin, tyrosine hydroxylase, calbindin and substance P in the human midbrain and substantia nigra in relation to nigrostriatal projections and differential neuronal susceptibility in Parkinson's disease. Brain Res. 1992;581:283-291.
105. Dahlstrom A, Fuxe K. Localization of monoamines in the lower brain stem. Experientia. 1964;20:398-399.
106. Gerfen CR, Herkenham M, Thibault J. The neostriatal mosaic: II. Patch- and matrix-directed mesostriatal dopaminergic and non-dopaminergic systems. J Neurosci. 1987;7:3915-3934.
107. Damier P, Hirsch EC, Agid Y, Graybiel AM. The substantia nigra of the human brain. I. Nigrosomes and the nigral matrix, a compartmental organization based on calbindin D(28K) immunohistochemistry [see comments]. Brain. 1999;122(Pt 8):1421-1436.
108. Costantini LC, Lin L, Isacson O. Medial fetal ventral mesencephalon: a preferred source for dopamine neuron grafts. Neuroreport. 1997;8:2253-2257.
109. Haque N, LeBlanc C, Isacson O. Differential dissection of the rat E16 ventral mesencephalon and survival and reinnervation of the 6-OHDA-lesioned striatum by a subset of aldehyde dehydrogenase-positive TH neurons. Cell Transplant. 1997;6:239-248.
110. Bjorklund L, Herlihy D, Isacson O. Cell and synaptic replacement therapy for Parkinson's disease: current status and future directions. Neurosci News. 2000;3:6-12.
111. Bjorklund LM, Isacson O. Regulation of dopamine cell type and transmitter function in fetal and stem cell transplantation for Parkinson's disease. Prog Brain Res. 2002;138:411-420.
112. Isacson O, Bjorklund LM, Schumacher JM. Toward full restoration of synaptic and terminal function of the dopaminergic system in Parkinson's disease by stem cells. Ann Neurol. 2003;53(3 suppl 1):S135-S148.
113. Ramachandran AC, Bartlett LE, Mendez IM. A multiple target neural transplantation strategy for Parkinson's disease. Rev Neurosci. 2002;13:243-256.